Ada Website Helper

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023

    Google releases new AI chatbot Bard to compete with ChatGPT

    February 6, 2023

    Elon Musk and Tesla found not liable in lawsuit over “funding secured” tweet

    February 4, 2023
    Facebook Twitter Instagram
    Ada Website Helper
    • Home
    • Autism

      Autism diagnosis rates have tripled in the last 16 years, says new study

      February 2, 2023

      Autism provider AnswersNow raises $11 million to expand state footprint

      February 2, 2023

      Autism Awareness Comes to Lawrence Police Headquarters – Trentonian

      February 2, 2023

      A felon charged with impersonating a therapist at Michigan autism treatment center ordered to trial

      February 2, 2023

      Autism Society Philippines and SM Cares Meet on Autism

      February 2, 2023
    • Disabilities

      Litigation improves accessibility to voters for people with print disabilities.news

      February 2, 2023

      Stress Relief and Mental Health Support

      February 2, 2023

      ‘Extraordinary’ Court Order Granted To Allow Severely Disabled Women To Attend Neurology Appointments – The Irish Times

      February 2, 2023

      Community Public Heath Liaison – Disability Scoop Jobs

      February 2, 2023

      People with disabilities in rural areas struggle to recover from recession | Conversation

      February 2, 2023
    • Disability

      Southern District of Georgia | Lawrence County man pays reparations and could face federal jail for disability fraud

      February 2, 2023

      Hitting the Snow with New Courses on Accessibility and Disability Justice

      February 2, 2023

      ASBMB Calls for Broad Federal Efforts to Support Scientists with Disabilities

      February 2, 2023

      State abortion bans based on gender, disability, or race are not a remedy for eugenics, paper says

      February 2, 2023

      New Guidance on Hearing Impairment in the Workplace – Monterey Herald

      February 2, 2023
    • Literature

      Seattle Department of Arts and Culture Names 2023-2024 Seattle Citizen Poet Xin Yu Pai

      February 2, 2023

      ‘Correct Prison Manual’: Female Baloch Inmates Released After Passing Baloch Literature Exam

      February 2, 2023

      Researchers use AI to make texts thousands of years old readable

      February 2, 2023

      “Dream in the Crimson Room” is performed as toe art

      February 2, 2023

      Literature and books: Portsmouth news and information (Portsmouth)

      February 2, 2023
    • Living

      Delicious Living Magazine double winner for Kiss My Faces Moisture Shave at the 2023 Beauty & Body Awards.

      February 2, 2023

      Tracy’s tutor sells Christine Quinn’s house in Sunset

      February 2, 2023

      The man lived in a garage before filming in Opa Locka

      February 2, 2023

      Barcaro Buffalo Living & Commerce Announces Pace Strength and Conditioning as New Tenant

      February 2, 2023

      Self Help – Estes Park Trail Gazette

      February 2, 2023
    • Society

      The Outer Banks Voice – Phi Island Preservation Society Announces Three Events Celebrating Black History

      February 2, 2023

      Peninsula Humane Society & SPCA Pet of the Week: Kesha and Gosha

      February 2, 2023

      SML Chapter of Antique and Classic Boat Association Holds Winter Workshop

      February 2, 2023

      Ida B. Wells Society moves from UNC-Chapel Hill to Morehouse College

      February 2, 2023

      Wilton Historical Society Weekend Workshop

      February 2, 2023
    Facebook Twitter Instagram
    Ada Website Helper
    Home»Autism»Psilocybin Therapy for Autism-like Disorder Receives Phase 2a Clinical Trial Approval
    Autism

    Psilocybin Therapy for Autism-like Disorder Receives Phase 2a Clinical Trial Approval

    adawebsitehelper_ts8fwmBy adawebsitehelper_ts8fwmDecember 28, 20222 Mins Read
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Partnership to lead psilocybin therapy for Fragile X Syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder (ASD) Health Canada in the form of no objection letter And we plan to proceed with the first-ever Phase 2a clinical trial of magic mushroom therapy for this condition.

    “A collaborative research team from the University of Rome Torre and the University of Nova Mentis found that microdosing psilocybin improved several aspects of cognitive performance in rats with fragile X syndrome (FXS), an autism-like disorder. Did.”#autism #FragileX https://t.co/dqVz8fbt9l

    — Nova Mentis Life Science Corp. (@NovaMentisLSC) December 14, 2022

    mental health care company Wellbeing Digital Science Co., Ltd. KonevSubsidiary of KGK Science Co., Ltd. and based in Canada Nova Mentis Life Sciences, Inc. NMLSF submitted clinical trial application (CTA) was submitted to Canadian health authorities this November.

    Wellbeing Subsidiary KGK Science Receives First-of-its-kind Psilocybin Clinical Trial Approval

    KGK has received approval from Health Canada for a Phase II clinical trial testing the efficacy of psilocybin for fragile X syndrome.$MEDI $KONEFhttps://t.co/3JOq8iJkSC

    — Jungle.java (@junglejava1) December 22, 2022

    of The transaction between the companies includes long-term contract research organization KGK Sciences providing repetitive oral microdoses of proprietary psilocybin in the form of 1.5 mg capsules to 10 participants in FXS, which will begin in early 2023. This includes conducting a Phase 2 clinical trial of Nova Mentis evaluating the therapy.

    “Over the past 25 years, our team at KGK has successfully assisted hundreds of companies with custom-designed clinical trials and proof-of-concept strategies that efficiently move their products to global markets. and Najla Guthrie, CEO of KGK, said:

    “Nova Mentis is the first company in the world to conduct a human trial to test the efficacy of psilocybin in adults diagnosed with Fragile X. We would like to collect the clinical data necessary for research related to autism.

    Nova Mentis’ goals include developing diagnostics and psilocybin-based therapies for neuroinflammatory diseases. It is the first biotechnology to achieve orphan drug designation in both the US and EU for the use of psilocybin in the treatment of FXS.

    The results of the open-label study will be used to support Nova’s drug development program under FDA orphan drug designation, which is expected to be received in the second half of 2021.

    __________

    This article originally appeared on Benzinga and is reprinted here with permission.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    adawebsitehelper_ts8fwm
    • Website

    Related Posts

    Autism February 2, 2023

    Autism diagnosis rates have tripled in the last 16 years, says new study

    Autism February 2, 2023

    Autism provider AnswersNow raises $11 million to expand state footprint

    Autism February 2, 2023

    Autism Awareness Comes to Lawrence Police Headquarters – Trentonian

    Autism February 2, 2023

    A felon charged with impersonating a therapist at Michigan autism treatment center ordered to trial

    Autism February 2, 2023

    Autism Society Philippines and SM Cares Meet on Autism

    Autism February 2, 2023

    Autism can be diagnosed within the first month of life

    Leave A Reply Cancel Reply

    Don't Miss
    News February 6, 2023

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    Under intense pressure to compete with ChatGPT — the much-talked-about AI chatbot that has become…

    Google releases new AI chatbot Bard to compete with ChatGPT

    February 6, 2023

    Elon Musk and Tesla found not liable in lawsuit over “funding secured” tweet

    February 4, 2023

    Delicious Living Magazine double winner for Kiss My Faces Moisture Shave at the 2023 Beauty & Body Awards.

    February 2, 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    About Us

    This website provides information about disability and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Our Picks

    Google Launches AI Chatbot Bard To Compete With ChatGPT

    February 6, 2023

    Google releases new AI chatbot Bard to compete with ChatGPT

    February 6, 2023

    Elon Musk and Tesla found not liable in lawsuit over “funding secured” tweet

    February 4, 2023

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    Facebook Twitter Instagram Pinterest
    • Home
    • Contact us
    • DMCA
    • Privacy Policy
    © 2023 adawebsitehelper. Designed b yadawebsitehelper.

    Type above and press Enter to search. Press Esc to cancel.